Concerning the immune microenvironment, YTHDF1 inhibits the recruitment of mature dendritic cells (DCs) in GC and suppresses antitumor immunity.[153] YTHDF1 deficiency mediates the upregulation of the JAK/STAT1 (Janus kinase/signal transducer and activator of transcription) pathway and promotes the expression of IFN-γ receptor 1, thereby enhancing antitumor immunity.[130] The loss of YTHDF1 induces persistent systemic antitumor immunity, and YTHDF1 may be highlighted as a possible therapeutic prospect in GC. Here, YTHDF1 is linked to gastric cancer.